Azitra, Inc. Form 8-K Summary
Business Context and Reporting Period
Azitra, Inc. (NYSE American: AZTR), a Delaware corporation, filed this Current Report on Form 8-K on February 4, 2025. The filing details a capital raise event where the Company entered into a placement agency agreement with Maxim Group LLC to sell shares of its common stock.
Key Financial Metrics
- Offering Size: 2,495,518 shares of Common Stock.
- Offering Price: $0.2785 per share.
- Gross Proceeds: Approximately $695,001.
- Placement Agent Fee: Up to 7.0% of aggregate gross proceeds.
- Closing Date: February 6, 2025.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transactional report rather than a periodic financial statement.
Material Changes and Agreements
The primary material change is the execution of an Amended and Restated Securities Purchase Agreement with investors. The Company agreed to specific lock-up provisions:
- 22-Day Restriction: From February 4, 2025, until 22 days after closing, the Company is restricted from issuing or announcing the issuance of Common Stock or equivalents (subject to exceptions).
- 45-Day Restriction: Until 45 days after closing, the Company is prohibited from effecting variable rate transactions involving Common Stock or equivalents (subject to exceptions).
Outlook, Risks, and Contingencies
The Company utilized a shelf registration statement on Form S-3 (File No. 333-280648), declared effective on July 8, 2024, to facilitate this offering. The filing includes customary representations, warranties, and indemnification obligations. No specific forward-looking guidance or new risk factors were disclosed in this specific filing beyond the standard terms of the purchase agreement.
Key Facts for Investor Verification
- Verify the net proceeds after deducting the 7.0% placement fee and other offering expenses.
- Confirm the dilution impact of the 2,495,518 new shares on existing shareholders.
- Review the full text of the Press Release (Exhibit 99.1) for management's stated use of proceeds.
- Monitor compliance with the 22-day and 45-day issuance restrictions outlined in the Purchase Agreement.